Lucemyra® (lofexidine hydrochloride) has recently been approved by the US FDA for the mitigation of withdrawal symptoms to facilitate abrupt discontinuation of opioids in adults. Lofexidine is an alpha-2 adrenoceptor agonist. However, the clinical attributes of lofexidine differ in advantageous ways from the classical alpha-2 adrenoceptor agonist clonidine. In the present study, we measured the receptor binding profile of lofexidine and clonidine in an effort to gain an insight into the clinical difference(s).
Introduction
The current "opioid crisis" has generated a renewed interest in evaluating the benefit-risk balance in patients' administered opioids appropriately, or persons' taking opioids as part of an opioid abuse disorder (OUD) [1] . This type of evaluation has increasingly resulted in the recommendation that the patients reduce their opioid regimen, or even eliminate it. In some cases, a patient may choose to voluntarily taper their opioid medication [2] . In other cases, a person who has an OUD might have to face the reality of an abstinence imposed upon them by the legal system [3] . In both cases, despite agreement about reducing opioid intake, fear of the unpleasant and distressing physiological sequelae that occur during withdrawal inhibits compliance [4] . Fear of the stigma, even of good-intentioned efforts, is also a barrier [5] . Thus, fear of withdrawal is a strong motivating factor Pharmacology & Pharmacy for resisting, or even avoiding, opioid taper and/or discontinuation [6] [7] .
For this reason, pharmacotherapy that might help ameliorate withdrawal symptoms during either voluntary or an imposed withdrawal can serve not only a beneficial physiological function, but might also be helpful in a psychological sense, offering the individual a more optimistic view of the decision to taper their legitimate or illegitimate opioid use. In the former case, this could assist in transition to non-opioid analgesics or non-pharmacologic treatment, and in the latter case could make the decision to seek treatment a little easier.
Traditional non-opioid pharmacologic treatment to ameliorate symptoms of opioid withdrawal has mainly involved the off-label use of clonidine. This is because there is a large release of norepinephrine during withdrawal from opioids ( Figure 1 ) [8] [9] [10] . Alpha-2 adrenoceptor agonists bind to presynaptic alpha-2 adrenoceptors and inhibit the release of norepinephrine. Clonidine is an alpha-2 adrenoceptor agonist [11] . Lofexidine is also an alpha-2 adrenoceptor agonist, but lofexidine's clinical attributes differ in several advantageous ways from clonidine [12] . The reason might be explained by differences in receptor binding.
In the present study, we report the binding affinity of lofexidine and clonidine in a variety of in vitro assays. In the assays in which the drugs were active, they displayed agonist activity (as determined by in vitro functional assays).
Methods
Lofexidine hydrochloride and clonidine hydrochloride were studied in a broad screen of receptor binding, uptake, and functional assays by Eurofins Scientific.
Vectors containing the receptors were transfected into HEK293 (human embryonic kidney 293) cells, and the assays were conducted according to methods previously published [13] - [19] .
The receptor binding affinity of compounds was calculated as the percent EC50 values (the concentrations of test compounds estimated to produce a half-maximal response in an assay) were determined by non-linear regression analysis of the concentration-response curves that were generated, with mean replicate values, using Hill equation curve fitting [20] .
Results
Clonidine and lofexidine were inactive in kappa opioid receptor assay (rat re- 
Discussion
For a significant number of people the fear of experiencing negative symptoms during voluntary or forced withdrawal from opioid therapy or abuse is a strong deterrent to seeking help or to compliance to effective tapering regimens, and the combination of uncomfortable symptoms and craving makes completion of withdrawal difficult [21] [22] [23] . Thus, a treatment that can lessen opioid withdrawal symptoms used in conjunction with other treatment modalities results in better outcomes [24] .
Based on several studies in rodents and monkeys suggesting that norepinephrine is involved in opioid withdrawal [25] 
Perspective and Conclusions
For a significant number of people, the fear of experiencing negative symptoms during withdrawal from opioids deters compliance with taper regimens and seeking treatment opportunities. Amelioration of withdrawal symptoms results in improved outcomes. The alpha-2 agonist lofexidine has been used for this purpose in several countries for many years, and has recently been approved in the US It is as effective as the standard alpha-2 agonist clonidine, but has a better safety profile. The present study potentially opens a window into a mechanistic understanding of the differentiating attributes of lofexidine and clonidine. Interestingly, the results of this study reveal that lofexidine, but not clonidine, has affinity for 5-HT 1A receptors. This is particularly interesting in light of studies demonstrating: 1) changes in 5-HT 1A mRNA during withdrawal, and 2) the decreased expression of morphine withdrawal symptoms in mice administered a compound having 5-HT 1A agonist activity.
Based on the above, it is intriguing to speculate that a drug that has dual agonist action at alpha-2 adrenoceptors and anxiolytic 5-HT 1A receptors will be more effective in treating opioid withdrawal symptoms at doses that produce less adverse effects than single-mechanism alpha-2 agonists.
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